Reyvow (Lasmiditan) Tablets Approved for Acute Migraine

Reyvow (Lasmiditan) Tablets Approved for Acute Migraine

The FDA has approved Reyvow (lasmiditan) tablets for the acute treatment of migraine with or without aura in adults. This drug is not indicated for the preventive treatment of migraine and can cause driving impairment, which is why Reyvow is pending controlled substance scheduling.

Reyvow is a serotonin (5-HT) 1F receptor agonist with recommended doses at 50 mg, 100 mg, or 200 mg, taken as needed, though no more than one dose should be taken in 24 hours. Reyvow may make its way into workers’ comp as migraines may be associated with workplace injuries.

Patients taking Reyvow should not drive or operate machinery until at least eight hours after taking each dose of Reyvow. Patients may not be able to assess their own driving competence and the degree of impairment caused by the drug. Other warnings and precautions include Central Nervous System (CNS) depression, serotonin syndrome, and headaches from overuse, which may require detox.

Common adverse reactions include dizziness, fatigue, paresthesia (abnormal dermal sensation like prickling or tingling), and sedation. Revyow may further lower heart rate when administered with heart rate lowering drugs and should not be co-prescribed with certain breast cancer medications.

For further information, read the FDA-approved drug label.